Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
7.53
+0.08 (1.14%)
Apr 1, 2026, 10:51 AM EDT - Market open
Kazia Therapeutics Employees
Kazia Therapeutics had 6 employees as of June 30, 2025. The number of employees decreased by 1 or -11.76% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-11.76%
Revenue / Employee
$211,072
Profits / Employee
-$2,534,761
Market Cap
85.99M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 6 | -1 | -11.76% |
| Jun 30, 2024 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortress Biotech | 101 |
| PolyPid | 73 |
| Seres Therapeutics | 66 |
| Aardvark Therapeutics | 40 |
| Vivani Medical | 37 |
| Gain Therapeutics | 25 |
| NeurAxis | 21 |
| Filana Therapeutics | 20 |
KZIA News
- 2 months ago - Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) - PRNewsWire
- 2 months ago - Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer - PRNewsWire
- 2 months ago - Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End - PRNewsWire
- 3 months ago - Kazia Therapeutics Regains Full Nasdaq Listing Compliance - PRNewsWire
- 4 months ago - Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+ - PRNewsWire
- 4 months ago - What's Going On With Cancer Firm Kazia Therapeutics - Benzinga
- 4 months ago - Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities - PRNewsWire
- 4 months ago - Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy - PRNewsWire